Author

D. Panovska

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Beck· 1 shared A. Claeys· 1 shared A. Martinez· 1 shared B. Bui· 1 shared B. Cole· 1 shared C. K. Petritsch· 1 shared D. Hambardzumyan· 1 shared D. Van Der Planken· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Beck

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BRAF/MEK Inhibition Induces Cell State Transitions Boosting Immune CheckpointSensitivity in BRAFV600E-mutant Glioma

Y. L. Xing, D. Panovska, J.-W. Park, S. Grossauer, K. Koeck, B. Bui, E. Nasajpour, J. J. Nirschl, Z.-P. Feng, P. Cheung, P. Habib, R. Wei, J. Wang, W. Thomason, J. Xiu, , C. K. Petritsch

This study shows that BRAF/MEK inhibition induces cell state transitions in BRAFV600E-mutant gliomas, leading to PD-L1 upregulation and immune evasion, which can be overcome by combining with immune checkpoint inhibition.

bioRxiv · Feb 3, 2023Cancer Biology

Single-cell molecular profiling using ex vivo functional readouts fuels precision oncology in glioblastoma

D. Panovska, P. Nazari, B. Cole, P.-J. Creemers, M. Derweduwe, L. Solie, S. Van Gassen, A. Claeys, T. Verbeke, Y. Saeys, D. Van Der Planken, F. M. Bosisio, E. Put, S. Bamps, P. Clement, , F. De Smet

The paper introduces PROSPERO, a single-cell assay to evaluate therapy response in glioblastoma by measuring molecular drug responses in fresh tumor samples, revealing limited therapeutic capacity and cellular plasticity.

bioRxiv · Oct 17, 2022 · PreprintCancer Biology